ric A Cohen

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7788567/eric-a-cohen-publications-by-year.pdf
Version: 2024-04-28

69 papers	2,990 citations	33 h-index	54 g-index
74 ext. papers	3,356 ext. citations	6.8 avg, IF	4.86 L-index

#	Paper	IF	Citations
69	Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.. *Journal of Virology*, **2022**, e0012822	6.6	7
68	LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy. *EBioMedicine*, **2021**, 65, 103270	8.8	15
67	L-Carnitine Tartrate Downregulates the ACE2 Receptor and Limits SARS-CoV-2 Infection. *Nutrients*, **2021**, 13,	6.7	7
66	RALDH Activity Induced by Bacterial/Fungal Pathogens in CD16 Monocyte-Derived Dendritic Cells Boosts HIV Infection and Outgrowth in CD4 T Cells. *Journal of Immunology*, **2021**, 206, 2638-2651	5.3	3
65	Human Immunodeficiency Virus Type 1 Vpr Mediates Degradation of APC1, a Scaffolding Component of the Anaphase-Promoting Complex/Cyclosome. *Journal of Virology*, **2021**, 95, e0097120	6.6	
64	HIV-1 Vpu Promotes Phagocytosis of Infected CD4 T Cells by Macrophages through Downregulation of CD47. *MBio*, **2021**, 12, e0192021	7.8	1
63	Lentiviral Infections Persist in Brain despite Effective Antiretroviral Therapy and Neuroimmune Activation.. *MBio*, **2021**, e0278421	7.8	3
62	The HIV-1 Accessory Protein Vpu Downregulates Peroxisome Biogenesis. *MBio*, **2020**, 11,	7.8	9
61	Pharmacological Inhibition of PPARy Boosts HIV Reactivation and Th17 Effector Functions, While Preventing Progeny Virion Release and de Infection. *Pathogens and Immunity*, **2020**, 5, 177-239	4.9	4
60	Interleukin-1β Triggers p53-Mediated Downmodulation of CCR5 and HIV-1 Entry in Macrophages through MicroRNAs 103 and 107. *MBio*, **2020**, 11,	7.8	3
59	HIV Infection and Persistence in Pulmonary Mucosal Double Negative T Cells. *Journal of Virology*, **2020**, 94,	6.6	5
58	Expression of MDM2 in Macrophages Promotes the Early Postentry Steps of HIV-1 Infection through Inhibition of p53. *Journal of Virology*, **2019**, 93,	6.6	9
57	Activation of the ILT7 receptor and plasmacytoid dendritic cell responses are governed by structurally-distinct BST2 determinants. *Journal of Biological Chemistry*, **2019**, 294, 10503-10518	5.4	6
56	Flt3L-Mediated Expansion of Plasmacytoid Dendritic Cells Suppresses HIV Infection in Humanized Mice. *Cell Reports*, **2019**, 29, 2770-2782.e5	10.6	9
55	HIV-1 is rarely detected in blood and colon myeloid cells during viral-suppressive antiretroviral therapy. *Aids*, **2019**, 33, 1293-1306	3.5	20
54	HIV-1 Vpr hijacks EDD-DYRK2-DDB1 to disrupt centrosome homeostasis. *Journal of Biological Chemistry*, **2018**, 293, 9448-9460	5.4	10
53	HIV-1 Vpu Downmodulates ICAM-1 Expression, Resulting in Decreased Killing of Infected CD4 T Cells by NK Cells. *Journal of Virology*, **2017**, 91,	6.6	15

52	Host MicroRNAs-221 and -222 Inhibit HIV-1 Entry in Macrophages by Targeting the CD4 Viral Receptor. *Cell Reports*, **2017**, 21, 141-153	10.6	37
51	Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain. *Retrovirology*, **2017**, 14, 47	3.6	40
50	Regulation of CD4 Receptor and HIV-1 Entry by MicroRNAs-221 and -222 during Differentiation of THP-1 Cells. *Viruses*, **2017**, 10,	6.2	9
49	HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy. *Aids*, **2017**, 31, 35-48	3.5	90
48	Conserved residues within the HIV-1 Vpu transmembrane-proximal hinge region modulate BST2 binding and antagonism. *Retrovirology*, **2017**, 14, 18	3.6	4
47	HIV-1 Viral Protein R Activates NLRP3 Inflammasome in Microglia: implications for HIV-1 Associated Neuroinflammation. *Journal of NeuroImmune Pharmacology*, **2017**, 12, 233-248	6.9	61
46	The evaluation of risk-benefit ratio for gut tissue sampling in HIV cure research. *Journal of Virus Eradication*, **2017**, 3, 212-217	2.8	7
45	Enhancing Virion Tethering by BST2 Sensitizes Productively and Latently HIV-infected T cells to ADCC Mediated by Broadly Neutralizing Antibodies. *Scientific Reports*, **2016**, 6, 37225	4.9	17
44	Remodeling of the Host Cell Plasma Membrane by HIV-1 Nef and Vpu: A Strategy to Ensure Viral Fitness and Persistence. *Viruses*, **2016**, 8, 67	6.2	37
43	Indoleamine 2,3-Dioxygenase-Expressing Aortic Plasmacytoid Dendritic Cells Protect against Atherosclerosis by Induction of Regulatory T Cells. *Cell Metabolism*, **2016**, 23, 852-66	24.6	58
42	Differential Control of BST2 Restriction and Plasmacytoid Dendritic Cell Antiviral Response by Antagonists Encoded by HIV-1 Group M and O Strains. *Journal of Virology*, **2016**, 90, 10236-10246	6.6	9
41	Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration. *Journal of Neuroscience*, **2016**, 36, 10683-10695	6.6	48
40	Assessing the Innate Sensing of HIV-1 Infected CD4+ T Cells by Plasmacytoid Dendritic Cells Using an Ex vivo Co-culture System. *Journal of Visualized Experiments*, **2015**,	1.6	1
39	Vpu Exploits the Cross-Talk between BST2 and the ILT7 Receptor to Suppress Anti-HIV-1 Responses by Plasmacytoid Dendritic Cells. *PLoS Pathogens*, **2015**, 11, e1005024	7.6	34
38	Attacking the Supply Lines: HIV-1 Restricts Alanine Uptake to Prevent T Cell Activation. *Cell Host and Microbe*, **2015**, 18, 514-7	23.4	6
37	HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2. *Retrovirology*, **2014**, 11, 15	3.6	85
36	From arrest to escape: HIV-1 Vpr cuts a deal. *Cell Host and Microbe*, **2014**, 15, 125-7	23.4	2
35	Defining the interactions and role of DCAF1/VPRBP in the DDB1-cullin4A E3 ubiquitin ligase complex engaged by HIV-1 Vpr to induce a G2 cell cycle arrest. *PLoS ONE*, **2014**, 9, e89195	3.7	15

34	Efficient BST2 antagonism by Vpu is critical for early HIV-1 dissemination in humanized mice. *Retrovirology*, **2013**, 10, 128	3.6	32
33	Viral protein R upregulates expression of ULBP2 on uninfected bystander cells during HIV-1 infection of primary CD4+ T lymphocytes. *Virology*, **2013**, 443, 248-56	3.6	13
32	Major histocompatibility complex class-II molecules promote targeting of human immunodeficiency virus type 1 virions in late endosomes by enhancing internalization of nascent particles from the plasma membrane. *Cellular Microbiology*, **2013**, 15, 809-22	3.9	5
31	Lentivirus Vpr and Vpx accessory proteins usurp the cullin4-DDB1 (DCAF1) E3 ubiquitin ligase. *Current Opinion in Virology*, **2012**, 2, 755-63	7.5	44
30	Extracellular human immunodeficiency virus type 1 viral protein R causes reductions in astrocytic ATP and glutathione levels compromising the antioxidant reservoir. *Virus Research*, **2012**, 167, 358-69	6.4	25
29	Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling. *Journal of Virology*, **2012**, 86, 3513-27	6.6	50
28	HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface. *Traffic*, **2011**, 12, 1714-29	5.7	44
27	Modulation of NKG2D-mediated cytotoxic functions of natural killer cells by viral protein R from HIV-1 primary isolates. *Journal of Virology*, **2011**, 85, 12254-61	6.6	12
26	HIV-1 Vpr induces the K48-linked polyubiquitination and proteasomal degradation of target cellular proteins to activate ATR and promote G2 arrest. *Journal of Virology*, **2010**, 84, 3320-30	6.6	41
25	HIV-1 viral protein R causes peripheral nervous system injury associated with in vivo neuropathic pain. *FASEB Journal*, **2010**, 24, 4343-53	0.9	49
24	MicroRNA profiling reveals new aspects of HIV neurodegeneration: caspase-6 regulates astrocyte survival. *FASEB Journal*, **2010**, 24, 1799-812	0.9	75
23	Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. *PLoS Pathogens*, **2010**, 6, e1000856	7.6	168
22	Formation of mobile chromatin-associated nuclear foci containing HIV-1 Vpr and VPRBP is critical for the induction of G2 cell cycle arrest. *PLoS Pathogens*, **2010**, 6, e1001080	7.6	49
21	Modulation of HIV-1-host interaction: role of the Vpu accessory protein. *Retrovirology*, **2010**, 7, 114	3.6	80
20	HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. *Blood*, **2010**, 115, 1354-63	2.2	119
19	Effect of calcium-modulating cyclophilin ligand on human immunodeficiency virus type 1 particle release and cell surface expression of tetherin. *Journal of Virology*, **2009**, 83, 13032-6	6.6	6
18	Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. *Journal of Virology*, **2009**, 83, 4574-90	6.6	120
17	Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases. *Virology*, **2008**, 372, 384-97	3.6	34

16	Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum. *Retrovirology*, **2007**, 4, 75	3.6	77
15	HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. *Journal of Neuroscience*, **2007**, 27, 3703-11	6.6	109
14	HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. *PLoS Pathogens*, **2007**, 3, e85	7.6	150
13	Productive human immunodeficiency virus type 1 assembly takes place at the plasma membrane. *Journal of Virology*, **2007**, 81, 7476-90	6.6	85
12	Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex. *Virus Research*, **2007**, 124, 103-12	6.4	14
11	Major histocompatibility complex class II molecules promote human immunodeficiency virus type 1 assembly and budding to late endosomal/multivesicular body compartments. *Journal of Virology*, **2006**, 80, 9789-97	6.6	24
10	Vpu exerts a positive effect on HIV-1 infectivity by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells. *Journal of Biological Chemistry*, **2003**, 278, 28346-53	5.4	60
9	Human Jurkat lymphocytes clones differ in their capacity to support productive human immunodeficiency virus type 1 multiplication. *Journal of Virological Methods*, **2001**, 92, 207-13	2.6	5
8	Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor. *Journal of Biological Chemistry*, **1999**, 274, 9083-91	5.4	83
7	Structural and functional analysis of the membrane-spanning domain of the human immunodeficiency virus type 1 Vpu protein. *Virology*, **1998**, 251, 96-107	3.6	57
6	Human immunodeficiency virus type 1 vpr protein transactivation function: mechanism and identification of domains involved. *Journal of Molecular Biology*, **1998**, 284, 915-23	6.5	62
5	Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. *Journal of Experimental Medicine*, **1998**, 187, 1103-11	16.6	120
4	Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells. *Journal of Virology*, **1998**, 72, 4686-93	6.6	148
3	Degradation of CD4 induced by human immunodeficiency virus type 1 Vpu protein: a predicted alpha-helix structure in the proximal cytoplasmic region of CD4 contributes to Vpu sensitivity. *Virology*, **1995**, 209, 615-23	3.6	48
2	Identification of a protein encoded by the vpu gene of HIV-1. *Nature*, **1988**, 334, 532-4	50.4	279
1	Implications of Spike-glycoprotein processing at S1/S2 by Furin, at S2□by Furin and/or TMPRSS2 and shedding of ACE2: cell-to-cell fusion, cell entry and infectivity of SARS-CoV-2		8